Drug intelligence / Profile preview

IMD-1

Development stage: Unknown
Lead developer: Takeda
Administration: Subcutaneous

Overview

IMD-1, also known by its trade name Immudron, is a novel immunomodulatory biologic agent designed to treat autoimmune disorders such as rheumatoid arthritis and lupus, as well as various inflammatory diseases. It operates by selectively targeting and modulating specific pathways within the immune system. Its mechanism of action involves binding to the CD28 receptor on T-cells, which inhibits their activation and proliferation. Additionally, IMD-1 has been shown to increase the production of regulatory T-cells (Tregs), which are crucial for maintaining immune tolerance and preventing autoimmunity. By rebalancing the immune system, IMD-1 helps to reduce inflammation and tissue damage associated with these conditions. The drug is currently in advanced stages of clinical trials.

Brand names: Immudron

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on IMD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMD-1.

Explore the full profile